CORONAVIRUS/Adimmune gets green light to start human trials of COVID-19 vaccine
08/20/2020 05:49 PM
Taipei, Aug. 20 (CNA) An experimental COVID-19 vaccine developed by Taiwanese maker Adimmune Corp. has been given the green light to start human trials, making it the first in the country to receive approval, Taiwan's Food and Drug Administration (FDA) said Thursday.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
More in CORONAVIRUS
![Taiwan reports 51 new COVID-19 cases, including 10 domestic infections]()
Taiwan reports 51 new COVID-19 cases, including 10 domestic infectionsTaiwan on Sunday reported 10 new domestic cases of COVID-19, as well as 41 imported cases, and no new deaths from the disease, according to the Central Epidemic Command Center ...01/16/2022 02:24 PM!['COVID pass' plan by city mayors must protect personal freedom: Minister]()
'COVID pass' plan by city mayors must protect personal freedom: MinisterMinister of Health and Welfare Chen Shih-chung (陳時中) said Saturday that two local governments, which are proposing to adopt the use of a digital COVID-19 certificate for entry to ...01/15/2022 11:04 PM![Over 750,000 appointments made for COVID-19 vaccine booster shot]()
Over 750,000 appointments made for COVID-19 vaccine booster shotMore than 750,000 people had made an appointment for a COVID-19 vaccine booster shot in the first seven hours after the central government's 1922 vaccination website was ...01/15/2022 10:33 PM
Latest
- Society
Hsinchu shopping mall closes due to confirmed COVID-19 case visit
01/16/2022 09:06 PM - Society
COVID-19 patients in Taoyuan visited retailers, rode city buses
01/16/2022 08:59 PM - Society
Migrant workers in Taiwan rally for freedom to change jobs
01/16/2022 08:52 PM - Sports
MLB Pittsburgh Pirates expected to sign Taiwan pitcher Chang Hung-leng
01/16/2022 08:28 PM - Society
Online bookings for COVID-19 vaccines to reopen Tuesday in Taiwan
01/16/2022 07:50 PM
